Literature DB >> 3085603

Cost-effectiveness of fine needle biopsy of the breast.

D R Lannin, J F Silverman, C Walker, W J Pories.   

Abstract

Although fine needle aspiration (FNA) biopsy of the breast has been shown to be a safe and accurate technique, many surgeons question whether it is reliable enough to replace excisional biopsy. If FNA biopsy is followed by excisional biopsy for confirmation, it would seem that the cost of diagnostic work-up would be increased. In this study, however, the authors show that the major economic benefit of FNA biopsy is not that it replaces excisional biopsy, but that it allows the surgeon to triage which patients should have a 1-stage inpatient procedure with frozen section and which patients should have an excisional biopsy as an outpatient under local anesthesia. Over the past 2 years, the average cost at the East Carolina University School of Medicine of excisional outpatient biopsy (negative) was +702 +/- 348; inpatient biopsy (negative) was +1410 +/- 262; inpatient 1-stage procedure (positive) was +4135 +/- 361; and outpatient biopsy (positive) followed by inpatient procedure was +4822 +/- 586. The authors' last 100 FNA biopsies were read as 23 positive, three suspicious, 65 negative, and nine insufficient. There were no false-positives and four false-negatives, for a sensitivity of 87%, specificity of 100%, and accuracy of 96%. Using the above figures, it is possible to calculate the cost per case if all 100 cases had been biopsied by the 1-stage inpatient technique (+2227), by the 2-stage outpatient method (+1938), or guided by the FNA biopsy where positive and suspicious readings are followed by an inpatient 1-stage procedure and negative and insufficient readings followed by an outpatient 2-stage procedure (+1759). Since the FNA biopsy costs +75, it resulted in a savings per case of +393 over routine inpatient biopsy and +104 per case over routine outpatient biopsy. Computer analysis revealed that the FNA biopsy would still be economically favorable if the sensitivity of the test fell as low as 37%, the specificity as low as 80%, or if the percentage of cases of cancer in the population biopsied fell as low as 13%. Since FNA biopsy is cost effective even when followed by an excisional or frozen section biopsy for confirmation, it would be safe and reasonable to expand its use to smaller hospitals where the personnel may be initially less experienced with the technique.

Entities:  

Mesh:

Year:  1986        PMID: 3085603      PMCID: PMC1251147          DOI: 10.1097/00000658-198605000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Breast biopsies on outpatients.

Authors:  T K Hunt; R A Crass
Journal:  Surg Gynecol Obstet       Date:  1975-10

2.  Outpatient breast biopsy.

Authors:  E C Saltzstein; R W Mann; T Y Chua; J J DeCosse
Journal:  Arch Surg       Date:  1974-08

3.  Aspiration cytology in the preoperative management of breast cancer.

Authors:  T I Gardecki; B M Hogbin; D H Melcher; R S Smith
Journal:  Lancet       Date:  1980-10-11       Impact factor: 79.321

4.  Breast biopsy: a study of cost-effectiveness.

Authors:  R C Doberneck
Journal:  Ann Surg       Date:  1980-08       Impact factor: 12.969

5.  Fine-needle aspiration of the breast: diagnoses and pitfalls. A review of 3545 cases.

Authors:  T S Kline; L P Joshi; H S Neal
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

6.  Sampling procedures in estrogen receptor determinations.

Authors:  J F Newsome; F P Avis; J E Hammond; S Sherwood
Journal:  Ann Surg       Date:  1981-05       Impact factor: 12.969

7.  Role of cytology in management of lesions of the breast.

Authors:  H T Strawbridge; A A Bassett; I Foldes
Journal:  Surg Gynecol Obstet       Date:  1981-01

8.  Breast biopsy. A comparison of outpatient and inpatient experience.

Authors:  G M Walker; R S Foster; C P McKegney; F P McKegney
Journal:  Arch Surg       Date:  1978-08

9.  Data favoring biopsy of the breast under local anesthesia.

Authors:  H H Caffee; J R Benfield
Journal:  Surg Gynecol Obstet       Date:  1975-01

10.  The diagnostic accuracy of palpation and fine-needle biopsy and an evaluation of their combined use in the diagnosis of breast lesions: report on a prospective study in 1244 women with symptoms.

Authors:  A Rimsten; B Stenkvist; H Johanson; A Lindgren
Journal:  Ann Surg       Date:  1975-07       Impact factor: 12.969

View more
  7 in total

1.  Significance of Flow Cytometric DNA Analysis from Freshly Aspirated Samples.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Complications of mastectomy and their relationship to biopsy technique.

Authors:  K A Lipshy; J P Neifeld; R M Boyle; W J Frable; S Ronan; P Lotfi; H D Bear; J S Horsley; W Lawrence
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

3.  Impact of Implementing Grading Fine Needle Aspiration Cytology in Diagnosis of Breast Cancer amongst Sudanese Women.

Authors:  Hussain Gadelkarim Ahmed
Journal:  Oman Med J       Date:  2011-03

4.  Evaluation of aspiration biopsy cytology and combined preoperative tests in the diagnosis of breast cancer.

Authors:  K Nakayama; R Abe; I Kimijima; T Watanabe; Y Furukawa; S Suzuki; K Urazumi; A Tsuchiya
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Analysis of residual cancer after diagnostic breast biopsy: an argument for fine-needle aspiration cytology.

Authors:  C E Cox; D S Reintgen; S V Nicosia; N N Ku; P Baekey; L C Carey
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

6.  Use of fine-needle aspiration in the evaluation of breast lumps.

Authors:  Mulazim Hussain Bukhari; Madiha Arshad; Shahid Jamal; Shahida Niazi; Shahid Bashir; Irfan M Bakhshi
Journal:  Patholog Res Int       Date:  2011-06-21

Review 7.  Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature.

Authors:  Suvradeep Mitra; Pranab Dey
Journal:  Cytojournal       Date:  2016-08-31       Impact factor: 2.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.